Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507894-16-00

Enrollment

6000

Registered

2024-08-23

Start date

2021-04-01

Completion date

Unknown

Last updated

2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

Percentage of patients that are included and treated based on their molecular tumour profile;, Percentage of patients that are included and treated based on their molecular tumour profile;, Treatment-related grade ≥3 and serious adverse events

Detailed description

Progression-free and overall survival, Duration of time on drug

Interventions

DRUGPhesgo 1200 mg/600 mg solution for injection

DRUGHYDROXYCARBAMIDE

DRUGRozlytrek 200 mg hard capsules

DRUGTabrecta 200 mg film-coated tablets

DRUGTEPMETKO 225 mg film-coated tablets

DRUGTecentriq 840 mg concentrate for solution for infusion

DRUGPhesgo 600 mg/600 mg solution for injection

DRUGAlecensa 150 mg hard capsules

DRUGIMATINIB

DRUGCotellic 20 mg film-coated tablets

DRUGCERITINIB

DRUGMekinist 0.5 mg film-coated tablets

DRUGFulvestrant SUN 250 mg injeksjonsvæske

DRUGoppløsning i ferdigfylt sprøyte

DRUGBORTEZOMIB

DRUGPiqray 200 mg film-coated tablets

DRUGLynparza 100 mg film-coated tablets

DRUGAvastin 25 mg/ml concentrate for solution for infusion.

DRUGRozlytrek 100 mg hard capsules

DRUGDEXAMETHASONE

DRUGRetsevmo 80 mg hard capsules

DRUGZelboraf 240 mg film-coated tablets

DRUGMELPHALAN

DRUGDACTINOMYCIN

DRUGPiqray 50 mg and 200 mg film-coated tablets

DRUGTecentriq 1 200 mg concentrate for solution for infusion

DRUGPemazyre 4.5 mg tablets

DRUGPiqray 150 mg film-coated tablets

DRUGDOSTARLIMAB

DRUGLynparza 150 mg film-coated tablets

DRUGMekinist 2 mg film-coated tablets

DRUGTafinlar 75 mg hard capsules

DRUGTecentriq 1 875 mg solution for injection

DRUGTabrecta 150 mg film-coated tablets

DRUGAMIVANTAMAB

DRUGNIRAPARIB

DRUGErivedge 150 mg hard capsules

DRUGRetsevmo 40 mg hard capsules

DRUGTafinlar 50 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of patients that are included and treated based on their molecular tumour profile;, Percentage of patients that are included and treated based on their molecular tumour profile;, Treatment-related grade ≥3 and serious adverse events	—

Secondary

Measure	Time frame
Progression-free and overall survival, Duration of time on drug	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026